Literature DB >> 8514873

Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2.

J Van de Water1, J Turchany, P S Leung, J Lake, S Munoz, C D Surh, R Coppel, A Ansari, Y Nakanuma, M E Gershwin.   

Abstract

Sera from patients with primary biliary cirrhosis (PBC) react with enzymes of the 2-oxo dehydrogenase pathways, particularly PDC-E2. These enzymes are present in all nucleated cells, yet autoimmune damage is confined to biliary epithelial cells. Using a panel of eight mouse monoclonal antibodies and a human combinatorial antibody specific for PDC-E2, we examined by indirect immunofluorescence and confocal microscopy sections of liver from patients with PBC, progressive sclerosing cholangitis, and hepatocarcinoma. The monoclonal antibodies gave typical mitochondrial immunofluorescence on biliary epithelium and on hepatocytes from patients with either PBC, progressive sclerosing cholangitis, or hepatocarcinoma. However, one of eight mouse monoclonal antibodies (C355.1) and the human combinatorial antibody reacted with great intensity and specificity with the luminal region of biliary epithelial cells from patients with PBC. Simultaneous examination of these sections with an antiisotype reagent for human IgA revealed high IgA staining in the luminal region of biliary epithelial cells in patients with PBC. IgG and IgA antibodies to PDC-E2 were detected in the bile of patients with PBC but not normal controls. We believe that this data may be interpreted as indicating that a molecule cross-reactive with PDC-E2 is expressed at high levels in the luminal region of biliary epithelial cells in PBC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514873      PMCID: PMC443329          DOI: 10.1172/JCI116504

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  Primary biliary cirrhosis. Inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1 alpha, a non-lipoic acid containing mitochondrial enzyme.

Authors:  D R Fregeau; T E Roche; P A Davis; R Coppel; M E Gershwin
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

Review 2.  The ubiquitin pathway of protein degradation and proteolysis of ubiquitin-protein conjugates.

Authors:  A Hershko
Journal:  Biochem Soc Trans       Date:  1991-08       Impact factor: 5.407

3.  Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis.

Authors:  D J Mutimer; S P Fussey; S J Yeaman; P J Kelly; O F James; M F Bassendine
Journal:  Hepatology       Date:  1989-10       Impact factor: 17.425

4.  Distribution of dihydrolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis: an immunohistochemical study.

Authors:  R Joplin; J G Lindsay; S G Hubscher; G D Johnson; J C Shaw; A J Strain; J M Neuberger
Journal:  Hepatology       Date:  1991-09       Impact factor: 17.425

5.  Hepatobiliary transport of plasma IgA in the mouse: contribution to clearance of intravascular IgA.

Authors:  D L Delacroix; G N Malburny; J P Vaerman
Journal:  Eur J Immunol       Date:  1985-09       Impact factor: 5.532

6.  Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis.

Authors:  S Cha; P S Leung; M E Gershwin; M P Fletcher; A A Ansari; R L Coppel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

7.  Membrane dihydrolipoamide acetyltransferase (E2) on human biliary epithelial cells in primary biliary cirrhosis.

Authors:  R Joplin; J G Lindsay; G D Johnson; A Strain; J Neuberger
Journal:  Lancet       Date:  1992-01-11       Impact factor: 79.321

8.  Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis.

Authors:  J Van de Water; A A Ansari; C D Surh; R Coppel; T Roche; H Bonkovsky; M Kaplan; M E Gershwin
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

9.  Autoimmune associations in primary biliary cirrhosis.

Authors:  K S Culp; C R Fleming; J Duffy; W P Baldus; E R Dickson
Journal:  Mayo Clin Proc       Date:  1982-06       Impact factor: 7.616

10.  Induction of autoreactive B cells allows priming of autoreactive T cells.

Authors:  R H Lin; M J Mamula; J A Hardin; C A Janeway
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

View more
  28 in total

Review 1.  Primary biliary cirrhosis. Connecting molecular biology to clinical medicine.

Authors:  S Reynoso-Paz; R L Coppel; Y Nakanuma; M E Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis.

Authors:  Jorge Allina; Bin Hu; Daniel M Sullivan; Maria Isabel Fiel; Swan N Thung; Steven F Bronk; Robert C Huebert; Judy van de Water; Nicholas F LaRusso; M E Gershwin; Gregory J Gores; Joseph A Odin
Journal:  J Autoimmun       Date:  2007-01-10       Impact factor: 7.094

3.  Transgenic mice aberrantly expressing pyruvate dehydrogenase complex E2 component on biliary epithelial cells do not show primary biliary cirrhosis.

Authors:  K Inamura; H Tsuji; Y Nakamoto; M Suzuki; S Kaneko
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Presence of disease specific autoantibodies against liver sinusoidal cells in primary biliary cirrhosis.

Authors:  Ourania Sfakianaki; Maria Tzardi; Argyro Voumvouraki; Aikaterini Afgoustaki; Meri Koulentaki; Elias Kouroumalis
Journal:  World J Hepatol       Date:  2013-10-27

5.  The ursodeoxycholic acid story in primary biliary cirrhosis.

Authors:  A G Lim; R P Jazrawi; T C Northfield
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

6.  Autoimmune cholangitis.

Authors:  J Heathcote
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

7.  Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis.

Authors:  K E Kisand; A L Karvonen; M Vuoristo; M Färkkilä; J Lehtola; J Inkovaara; K V Kisand; T Miettinen; K Krohn; R Uibo
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

Review 8.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

9.  Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease.

Authors:  Kanji Wakabayashi; Zhe-Xiong Lian; Patrick S C Leung; Yuki Moritoki; Koichi Tsuneyama; Mark J Kurth; Kit S Lam; Katsunori Yoshida; Guo-Xiang Yang; Toshifumi Hibi; Aftab A Ansari; William M Ridgway; Ross L Coppel; Ian R Mackay; M Eric Gershwin
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

10.  Random phage mimotopes recognized by monoclonal antibodies against the pyruvate dehydrogenase complex-E2 (PDC-E2).

Authors:  S Cha; P S Leung; J Van de Water; K Tsuneyama; R E Joplin; A A Ansari; Y Nakanuma; P J Schatz; S Cwirla; L E Fabris; J M Neuberger; M E Gershwin; R L Coppel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.